Cardlytics (NASDAQ:CDLX) CEO Amit Gupta Sells 68,260 Shares

Key Points

• Cardlytics CEO Amit Gupta sold 68,260 shares of the company's stock for a total of $76,451.20, reducing his ownership by 10.86% to 560,444 shares valued at approximately $627,697.28.
• The company's stock is currently trading at $1.10, with a 52-week range between $1.0338 and $5.2450, and analysts have set an average price target of $2.25.
• Institutional investors and hedge funds hold a significant stake in Cardlytics, owning 68.10% of the company's stock, with various firms increasing their positions recently.

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CEO Amit Gupta sold 68,260 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $1.12, for a total value of $76,451.20. Following the completion of the sale, the chief executive officer owned 560,444 shares of the company's stock, valued at approximately $627,697.28. This represents a 10.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Amit Gupta also recently made the following trade(s):

• On Tuesday, August 19th, Amit Gupta sold 68,685 shares of Cardlytics stock. The shares were sold at an average price of $1.12, for a total transaction of $76,927.20.
• On Wednesday, July 2nd, Amit Gupta sold 6,725 shares of Cardlytics stock. The shares were sold at an average price of $1.78, for a total transaction of $11,970.50.

Cardlytics Stock Performance

NASDAQ CDLX traded up $0.10 during trading on Friday, reaching $1.11. The company's stock had a trading volume of 807,503 shares, compared to its average volume of 1,447,929. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.16 and a current ratio of 1.16. The firm has a market cap of $59.10 million, a price-to-earnings ratio of -0.30 and a beta of 1.26. Cardlytics, Inc. has a twelve month low of $0.95 and a twelve month high of $5.2450. The business's fifty day moving average price is $1.74 and its 200-day moving average price is $1.95.

Institutional Investors Weigh In On Cardlytics

Several large investors have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its stake in shares of Cardlytics by 46.0% during the fourth quarter. Wells Fargo & Company MN now owns 21,106 shares of the company's stock valued at $78,000 after acquiring an additional 6,649 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Cardlytics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,060,739 shares of the company's stock valued at $3,936,000 after acquiring an additional 7,561 shares during the last quarter. Post Resch Tallon Group Inc. boosted its stake in shares of Cardlytics by 100.0% during the second quarter. Post Resch Tallon Group Inc. now owns 20,000 shares of the company's stock valued at $33,000 after acquiring an additional 10,000 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of Cardlytics by 12.5% during the fourth quarter. Two Sigma Investments LP now owns 94,901 shares of the company's stock valued at $352,000 after acquiring an additional 10,508 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its position in Cardlytics by 44.1% during the fourth quarter. Two Sigma Advisers LP now owns 36,900 shares of the company's stock worth $137,000 after buying an additional 11,300 shares during the period. Hedge funds and other institutional investors own 68.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on CDLX shares. Lake Street Capital dropped their price objective on shares of Cardlytics from $3.00 to $2.50 and set a "hold" rating on the stock in a research note on Thursday, May 8th. Evercore ISI cut their price target on Cardlytics from $3.00 to $2.00 and set an "in-line" rating for the company in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $2.25.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.